Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2015. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, in accordance with DTR 3.1.4 R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of director share transactions and contains no financial performance data.
Material Changes
The filing discloses a change in the shareholding interest of Mr. S Dingemans, an Executive Director. On May 14, 2015, Mr. Dingemans transferred 40,000 Ordinary Shares held under a personal shareholding account to a Corporate Sponsored Nominee.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Executive Director S Dingemans transferred 40,000 Ordinary Shares to a Corporate Sponsored Nominee on May 14, 2015.
- The transaction was reported to the Company on May 15, 2015.
- This filing contains no financial results or strategic updates for the period.